Highlights Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
23.35 ^USD	+2.55%		+21.87%	-16.76%

Apr. 15	Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating	MT
Apr. 12	Pharvaris Files Mixed Shelf	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharvaris Narrows Q4 Net Loss; Hires New CFO	Apr. 10	MT
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant	Jan. 22	DJ
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks	Jan. 22	CI
Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023	Dec. 08	CI
Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks	Dec. 06	CI
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting	Nov. 09	CI
Pharvaris N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Pharvaris N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Pharvaris Says US FDA Lifts Clinical Hold on Application for Rare Disorder Drug	23-06-26	MT
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE	23-06-26	CI
Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023	23-06-10	CI
Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-05	CI
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the on Demand Treatment of HAE Attacks at AAAAI Annual Meeting	23-02-24	CI
Pharvaris N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-08	CI
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks	22-12-08	CI
Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop	22-10-07	CI
Pharvaris Q2 Loss Narrows	22-09-12	MT
Pharvaris N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Highlights

Filters